- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07943468
Extended Platelet-Rich Fibrin Membrane Versus Resorbable Novel Magnesium Membrane for Horizontal Ridge Augmentation With Simultaneous Implant Placement
Effectiveness Of Extended Platelet-Rich Fibrin Membrane Versus Resorbable Novel Magnesium Membrane for Horizontal Ridge Augmentation With Simultaneous Implant Placement
This study performed to evaluate and compare the effectiveness ofextended platelet-rich fibrin (ePRF) and novel magnesium membrane in horizontal ridge augmentation with simultaneous implant placement clinically and radiographically
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
The phenomenon of horizontal and vertical ridge resorption, following tooth extraction, has been extensively investigated. Different augmentation techniques have been developed to overcome this phenomenon on localization, extent, and configuration of the bone defect. These include insertion of bone grafts or barrier membranes in terms of guided bone regeneration.
The advancement Of guided bone regeneration has significantly expanded the range of implant applications to be a highly reliable treatment option even in areas of the jaw bone don't have sufficient bone support.The predictability that just attained if this process is successful, it could change the treatment of a compromised patient into a nearly normal challenge. Various have described to reconstruct deficient alveolar ridges. In the simultaneous treatment approach, guided bone regeneration is associated with superior outcomes when compared to other procedures and has become the treatment Of choice to provide optimal support for dental implants.
The primary alternative to an autograft is the use of allograft materials, which can obtained from either a compatible living donor or from cadaveric bone sources. Allograft materials can be prepared in three primary forms: fresh, frozen, or freeze-dried. Fresh and frozen allograft materials possess superior osteoinductive but are rarely used nowadays due to the higher risk Of a host immunogenic response, limited shelf life, and increased risk of disease transmission. Further processing of allograft material through freeze-drying can increase the shelf life of the material and decrease the immunogenicity, though at the cost of decreased osteoinductive potential, decreased structural strength, and osseointegration. Allografts have been successfully used for guided bone regeneration in bone augmentation procedure. This study performed to evaluate and compare the effectiveness of extended platelet-rich fibrin and novel magnesium membrane in horizontal ridge augmentation with simultaneous implant placement clinically and radiographically
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
Al Mansurah, Egypte
- Mansoura university
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Horizontal bone width <6 mm an s than 3 mm at crest
- Sufficient vertical bone height for implant placement.
- Healthy and sufficient width Of keratini7Æd mucosa.
- Maxillary or mandibular edentulous space sufficient for prosthesis according to teeth to be restored. All patients are between 18 and 60 years
Exclusion Criteria:
- General contraindication for implant placement and/or surgical treatment.
- Ongoing Inflammatory and/or autoimmune disease of the oral cavity.
- Immunosuppressant, corticosteroid or bisphosphonate therapy.
- History of malignancy, radiotherapy or chemotherapy for treatment of malignancy within the past 5 years.
- Smokers.
- Insulin- dependent diabetes
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Group l
Group l: It will include 10 patients and they will be treated with delayed implant placement combined With guided bone regeneration and pericardium membrane (maxxeus). |
Group l: It will include 10 patients and they will be treated with delayed implant placement combined With guided bone regeneration by freeze dried bone allograft (maxgraft granules, botiss biomaterials GmbH, Berlin, Germany, part of Straumann Group, Basel, Switzerland) and pericardium membrane (maxxeus). |
|
Experimenteel: Group II
Group II: It will include 10 patients and they will be treated with delayed implant placement combined With guided bone regeneration by dried freeze allograft and (e-PRF) membrane |
Group II: It will include 10 patients and they will be treated with delayed implant placement combined With guided bone regeneration by freeze dried bone allograft part of Straumann Group, Basel, Switzerland) and (e-PRF) membrane. |
|
Experimenteel: Group III
Group III: It will include 10 patients and they will treated with delayed implant placement combined with GBR by dried freeze bone allograft DFBA and novel magnesium membrane NOVAMag |
roup III: It will include 10 patients and they will treated with delayed implant placement combined with guided bone regeneration by dried freezed bone allograft (maxgraft granules, botiss biomaterials GmbH, Berlin, Germany, part of Straumann Group, Basel, Switzerland) and novel magnesium membrane NOVAMag |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Radiographic assessment by cone beam computed tomography
Tijdsspanne: immediately postoperatively , at the 5-8 months postoperative and at one year postoperative
|
immediately postoperatively , at the 5-8 months postoperative and at one year postoperative
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Status of the peri-implant soft tissues (probing depth )
Tijdsspanne: 2 months and 6 months after loading.
|
2 months and 6 months after loading.
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Andere studie-ID-nummers
- A010120230M
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
It will be available if it needed
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
- ICF
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .